Clinical Trial Update: Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating lapatinib with carboplatin and paclitaxel in esophagus and GEJ adenocarcinoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Adenocarcinoma of the Gastroesophageal Junction

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lapatinib (Lapatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-02-26